Anti-proliferative and pro-apoptotic effects of GHRH antagonists in prostate cancer

Oncotarget

Volumn 7, Issue 32, 2016, Pages 52195-52206

  Muñoz Moreno, Laura ^a   Arenas, Maria Isabel ^a   Carmena, María J ^a   Schally, Andrew V ^b,c   Sánchez Chapado, Manuel ^a,d   Prieto, Juan C ^a   Bajo, Ana M ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

Author keywords

Apoptosis; Cell proliferation; GHRH; GHRH antagonists; Prostate cancer therapy

Indexed keywords

CASPASE 3; CYCLIN D1; CYCLINE; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE RELEASING FACTOR RECEPTOR; GROWTH HORMONE RELEASING HORMONE ANTAGONIST; HERMES ANTIGEN; HORMONE ANTAGONIST; JMR 132; JV 1 38; MYC PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; GHRH(1-29)NH2, PHACTYR(1)-ARG(2)-P(H)E(4-CL)(6)-ALA(8)-TYR(ME)(10)-HIS(11)-ABU(15)-HIS(20)-NLE(27)-ARG(28)-HLCR(29)-; JV 1-38; SERMORELIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; HISTOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LNCAP CELL LINE; MALE; MOUSE; MTT ASSAY; NONHUMAN; PC3 CELL LINE; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROSTATE EPITHELIUM CELL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; RWPE 1 CELL LINE; TUMOR XENOGRAFT; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG SCREENING; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; GROWTH HORMONE-RELEASING HORMONE; HUMANS; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; SERMORELIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84982282523     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10710     Document Type: Article

References (40)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65:5-29.
2. Chen FZ, Zhao XK. Prostate Cancer: Current Treatment and Prevention Strategies. Iran Red Crescent Med J. 2013; 15:279-284.
3. Schally AV, Varga JL, Engel JB. Antagonists of growthhormone-releasing hormone: an emerging new therapy for cancer. Nat Clin Pract Endocrinol Metab. 2008; 4:33-43.
4. Kiaris H, Chatzistamou I, Papavassiliou AG, Schally AV. Growth hormone-releasing hormone: not only a neurohormone. Trends Endocrinol Metab. 2011; 22:311-317.
5. Havt A, Schally AV, Halmos G, Varga JL, Toller GL, Horvath JE, Szepeshazi K, Köster F, Kovitz K, Groot K, Zarandi M, Kanashiro CA. The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues. Proc Natl Acad Sci U S A. 2005; 102:17424-17429.
6. Toller GL, Horvath JE, Schally AV, Halmos G, Varga JL, Groot K, Chism D, Zarandi M. Development of a polyclonal antiserum for the detection of the isoforms of the receptors for human growth hormone-releasing hormone on tumors. Proc Natl Acad Sci U S A. 2004; 101:15160-15165.
7. Rekasi Z, Czompoly T, Schally AV, Halmos G. Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers. Proc Natl Acad Sci U S A. 2000; 97:10561-10566.
8. Siejka A, Lawnicka H, Melen-Mucha G, Motylewska E, Komorowski J, Stepien H. Antineoplastic action of growth hormone-releasing hormone (GHRH) antagonists. Recent Pat Anticancer Drug Discov. 2012; 7:56-63.
9. Fahrenholtz CD, Rick FG, Garcia MI, Zarandi M, Cai RZ, Block NL, Schally AV, Burnstein KL. Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer. Proc Natl Acad Sci U S A. 2014; 111:1084-1089.
10. Bellyei S, Schally AV, Zarandi M, Varga JL, Vidaurre I, Pozsgai E. GHRH antagonists reduce the invasive and metastatic potential of human cancer cell lines in vitro. Cancer Lett. 2010; 293:31-40.
11. Szepeshazi K, Schally AV, Groot K, Armatis P, Hebert F, Halmos G. Antagonists of growth hormone-releasing hormone (GH-RH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumours. Eur J Cancer. 2000; 36:128-136.
12. Muñoz-Moreno L, Arenas MI, Schally AV, Zarka E, González-Santander M, Carmena MJ, Vacas E, Prieto JC, Bajo AM. Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer. Int J Cancer. 2013; 132:755-765.
13. Fernández-Martínez AB, Bajo AM, Valdehita A, Sánchez-Chapado M, Carmena MJ, Prieto JC. Multifunctional role of VIP in prostate cancer progression in a xenograft model: Suppression by curcumin and COX-2 inhibitor NS-398. Peptides. 2009; 30:2357-2364.
14. Kirby RS, Partin AW, Feneley M, Parsons JK. Prostate Cancer: Principles and Practice: Taylor & Francis, New York. 2006.
15. Maga G, Hubscher U. Proliferating cell nuclear antigen (PCNA): a dancer with many partners. J Cell Sci. 2003; 116:3051-3060.
16. Wang SC. PCNA: a silent housekeeper or a potential therapeutic target? Trends Pharmacol Sci. 2014; 35:178-186.
17. Moldovan GL, Pfander B, Jentsch S. PCNA, the maestro of the replication fork. Cell. 2007; 129:665-679.
18. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009; 9:400-414.
19. Pérez-Sayáns M, Suárez-Peñaranda JM, Gayoso-Diz P, Barros-Angueira F, Gándara-Rey JM, García-García A. The role of p21Waf1/CIP1 as a Cip/Kip type cell-cycle regulator in oral squamous cell carcinoma (Review). Med Oral Patol Oral Cir Bucal. 2013; 18:e219-225.
20. Mirzayans R, Andrais B, Scott A, Murray D. New insights into p53 signaling and cancer cell response to DNA damage: implications for cancer therapy. J Biomed Biotechnol. 2012; 2012:170325.
21. Zarandi M, Varga JL, Schally AV, Horvath JE, Toller GL, Kovacs M, Letsch M, Groot K, Armatis P, Halmos G. Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities. Proc Natl Acad Sci U S A. 2006; 103:4610-4615.
22. Rick FG, Schally AV, Szalontay L, Block NL, Szepeshazi K, Nadji M, Zarandi M, Hohla F, Buchholz S, Seitz S. Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases. Proc Natl Acad Sci U S A. 2012; 109:1655-1660.
23. Seitz S, Rick FG, Schally AV, Treszl A, Hohla F, Szalontay L, Zarandi M, Ortmann O, Engel JB, Buchholz S. Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triplenegative breast cancers. Oncol Rep. 2013; 30:413-418.
24. Pozsgai E, Schally AV, Hocsak E, Zarandi M, Rick F, Bellyei S. The effect of a novel antagonist of growth hormone releasing hormone on cell proliferation and on the key cell signaling pathways in nine different breast cancer cell lines. Int J Oncol. 2011; 39:1025-1032.
25. Szalontay L, Schally AV, Popovics P, Vidaurre I, Krishan A, Zarandi M, Cai RZ, Klukovits A, Block NL, Rick FG. Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function. Cell Cycle. 2014; 13:2790-2797.
26. Siejka A, Schally AV, Block NL, Barabutis N. Antagonists of growth hormone-releasing hormone inhibit the proliferation of human benign prostatic hyperplasia cells. Prostate. 2010; 70:1087-1093.
27. Siejka A, Barabutis N, Schally AV. GHRH antagonist MZ-5-156 increases the expression of AMPK in A549 lung cancer cells. Cell Cycle. 2011; 10: 3714-3718.
28. Buchholz S, Schally AV, Engel JB, Hohla F, Heinrich E, Koester F, Varga JL, Halmos G. Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel. Proc Natl Acad Sci U S A. 2007; 104:1943-1946.
29. Rick FG, Seitz S, Schally AV, Szalontay L, Krishan A, Datz C, Stadlmayr A, Buchholz S, Block NL, Hohla F. GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer. Cell Cycle 2012; 11:4203-4210.
30. Stoimenov I, Helleday T. PCNA on the crossroad of cancer. Biochem Soc Trans. 2009; 37:605-613.
31. Garcia-Fernandez MO, Schally AV, Varga JL, Groot K, Busto R. The expression of growth hormone-releasing hormone (GHRH) and its receptor splice variants in human breast cancer lines; the evaluation of signaling mechanisms in the stimulation of cell proliferation. Breast Cancer Res Treat. 2003; 77:15-26.
32. Hohla F, Buchholz S, Schally AV, Seitz S, Rick FG, Szalontay L, Varga JL, Zarandi M, Halmos G, Vidaurre I, Krishan A, Kurtoglu M, Chandna S, et al. GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells. Cell Cycle. 2009; 8:3149-3156.
33. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: Cyclin D1: normal and abnormal functions. Endocrinology. 2004; 145:5439-5447.
34. Cotter TG. Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer. 2009; 9:501-507.
35. Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT, Liu B, Bao JK. Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif. 2012; 45:487-498.
36. Esfahani M, Ataei N, Panjehpour M. Biomarkers for Evaluation of Prostate Cancer Prognosis. Asian Pac J Cancer Prev. 2015; 16:2601-2611.
37. Kim JY, Valencia T, Abu-Baker S, Linares J, Lee SJ, Yajima T, Chen J, Eroshkin A, Castilla EA, Brill LM, Medvedovic M, Leitges M, et al. c-Myc phosphorylation by PKC? represses prostate tumorigenesis. Proc Natl Acad Sci U S A. 2013; 110:6418-6423.
38. Dang CV. MYC on the path to cancer. Cell. 2012; 149:22-35.
39. Marhaba R, Zöller M. CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol. 2004; 35:211-231.
40. Varga JL, Schally AV, Csernus VJ, Zarándi M, Halmos G, Groot K, Rékási Z. Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities. Proc Natl Acad Sci U S A. 1999; 96:692-697.